AB-101 as Monotherapy and With Immunotherapy in Patients With Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

NCT04673617 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

45

Enrollment

INDUSTRY

Sponsor class

Conditions

Non Hodgkin Lymphoma

Interventions

DRUG: AB-101
DRUG: Rituximab
DRUG: Interleukin-2
DRUG: Cyclophosphamide
DRUG: Fludarabine
DRUG: Bendamustine

Sponsor

Artiva Biotherapeutics, Inc.